Validation of Patras Immunotherapy Score model for prediction and prognosis of patients with advanced NSCLC treated with nivolumab or pembrolizumab: results from a European multicentre study

BACKGROUND: Recently, the Patras Immunotherapy Score (PIOS) has been developed to estimate the survival benefit of patients with advanced non-small-cell lung cancer (aNSCLC) treated with nivolumab or pembrolizumab. The aim of this study was to validate the clinical value of PIOS in an external cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Dimitrakopoulos, Foteinos-Ioannis, Mountzios, Giannis, Christopoulos, Petros, Papastergiou, Thomas, Elshiaty, Mariam, Daniello, Lea, Zervas, Elefterios, Agelaki, Sofia, Samantas, Epaminondas, Nikolaidi, Adamantia, Athanasiadis, Ilias, Baka, Sofia, Syrigos, Konstantinos, Christopoulou, Athina, Lianos, Evangelos, Samitas, Konstantinos, Tsoukalas, Nikolaos, Perdikouri, Eleni-Isidora, Oikonomopoulos, George, Kottorou, Anastasia, Kalofonou, Foteini, Makatsoris, Thomas, Koutras, Angelos, Megalooikonomou, Vasileios, Kalofonos, Haralabos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Immunotherapy for Lung Cancer: Progress, Opportunities and Challenges
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465562/
https://www.ncbi.nlm.nih.gov/pubmed/36105886
http://dx.doi.org/10.1177/17588359221122728

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9465562/
https://www.ncbi.nlm.nih.gov/pubmed/36105886
http://dx.doi.org/10.1177/17588359221122728

Ejemplares similares